Lundbeck presents Phase Ib data for Lu AF28996 in advanced Parkinson's disease, as Phase II trial begins
Results from an 18-week, open-label Phase Ib trial of investigational Lu AF28996 in people with advanced Parkinson's disease are being presented at MDS 2026 The trial provided initial safety and tolerability data for Lu AF28996, with most...
Lundbeck to showcase progress across its movement disorders pipeline with data in multiple system atrophy and Parkinson's disease at MDS® 2026
Late-breaking Phase III MASCOT oral presentation will characterize the clinical profile and diversity of participants in Lundbeck's ongoing global Phase III trial investigating amlenetug in multiple system atrophy (MSA) New research across clinical...
Lundbeck to establish global innovation hub in Greater Boston and relocate US headquarters
The new hub in Greater Boston will bring Lundbeck closer to one of the world's leading life sciences ecosystems, strengthening access to science, talent and partnerships. The move is part of Lundbeck's continued investment in the US, a key market,...
Lundbeck announces last patient randomized in DEEp OCEAN, a large Phase III trial in developmental and epileptic encephalopathies (DEEs)
DEEp OCEAN is a global trial designed to evaluate the investigational molecule bexicaserin for the treatment of seizures associated with DEEs, a diverse group of childhood-onset epilepsies1 Broadest pivotal trial to date, enrolling patients with a...
Tarek Samad appointed EVP, Head of Research & Development at Lundbeck
VALBY, Denmark, June 24, 2026 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today announced that Tarek Samad has been appointed Executive Vice President and Head of Research & Development (R&D) and will join the Executive Leadership Team (ELT)...
Lundbeck presents new Vyepti® (eptinezumab) and bocunebart migraine portfolio data at EAN 2026
Five migraine presentations will showcase Lundbeck's current and future approaches to migraine prevention, including new data for eptinezumab and Phase IIb PROCEED primary data for the investigational treatment, bocunebart Eptinezumab data explore...
Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in South Korea for the preventive treatment of migraine
Approval granted by South Korea's Ministry of Food and Drug Safety (MFDS) Eptinezumab is an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody for the preventive treatment of migraine in adults Authorization supported by the Phase 3...
Lundbeck receives orphan drug designation in Japan for asedebart for the treatment of patients with congenital adrenal hyperplasia and Cushing's disease
Congenital adrenal hyperplasia (CAH) and Cushing's disease (CD) are rare disorders characterized by excess adrenocorticotropic hormone (ACTH) produced in the brain1,2 Current treatments are limited by suboptimal disease control and treatment-related...
Lundbeck presents new data at AAN 2026 highlighting real-world changes in migraine-related cognitive symptoms after starting VYEPTI® (eptinezumab)
• The one-year INFUSE study observed patient-reported migraine-related cognitive symptoms at baseline and changes over 6 months in those with at least one prior anti-calcitonin gene-related peptide (anti-CGRP) treatment failure VALBY, Denmark, April...
Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan
VALBY, Denmark, March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple...